This page shows the latest neurodegeneration news and features for those working in and with pharma, biotech and healthcare.
assets,” said Mark Mintun, vice president of pain and neurodegeneration research at Lilly.
The scientific team at Disarm discovered an important and highly promising approach to combat axonal degeneration,” said Mark Mintun, vice president of pain and neurodegeneration research at Lilly. ... Lilly has previously tried its hand in
Genkyotex’s platform identifies small molecules which can selectively inhibit specific NOX enzymes that amplify multiple disease processes including fibrosis, inflammation, pain processing, cancer development and neurodegeneration.
Mutations in the LRRK2 gene, a regulator of lysosomal function, can cause Parkinson’s disease and is thought to contribute to neurodegeneration.
Expands into early-stage neurodegeneration research field. Merck has taken a stake in the neurodegeneration research field, following the acquisition of San-Diego, US-based Calporta. .
GeNeuro opted to continue dosing patients in the open-label follow-up, and now says temelimab provided continued relative improvements in neurodegeneration measured by magnetic resonance imaging (MRI), including a reduction
More from news
Approximately 2 fully matching, plus 28 partially matching documents found.
Two proteins – Tau and beta-amyloid – are recognised as major hallmarks of neurodegeneration: tangles and other abnormal forms of Tau protein accumulate inside the brain cells and spread between cells, while ... Secondly, it is well understood that
US biotech company Alector, which is pioneering work in immuno-neurology and novel therapeutic approaches to treating neurodegeneration, raised $176m in an initial public offering in early February. ... Alector has devoted the last five years to the
Dicerna/. Lilly. GalXC RNAi technology platform for targets in Cardiometabolic disease, neurodegeneration and pain.
dopamine due to neurodegeneration.
abnormalities including seizures, neurodegeneration, cognitive deficits and hypomyelination…it is completely unclear whether BACE could be targeted in a manner to affect amyloid processing in a therapeutic manner, without serious
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Importantly, this team will help us maintain focus as we work to bring forward new medicines in diabetes, cancer, immunology, neurodegeneration and pain.”.
He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience development franchise and therapeutic head for neurodegeneration since 2011.
Prior to this, she was the global head of neurodegeneration at Novartis, and worked in the healthcare sector of McKinsey &Company in Chicago.
Dr Murray (pictured above) brings over 20 years of drug discovery and early development experience to the role, spread across a range of therapeutic areas including dermatology, inflammation, neurodegeneration, psychiatry.
including neurodegeneration, neuroinflammation and central nervous system inherited diseases.
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
As it is easier to prevent neurodegeneration (neuron death) than to reverse it, neuroscientists are starting to look for early markers, through genetic tests or blood tests, in order to diagnose
The pathogenesis of MS consists of two key components: focal inflammatory demyelination, and neurodegeneration.
The pathogenesis of MS consists of two key components: focal inflammatory demyelination, and neurodegeneration.
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...